Neoplasms, Unknown Primary
"Neoplasms, Unknown Primary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Metastases in which the tissue of origin is unknown.
| Descriptor ID |
D009382
|
| MeSH Number(s) |
C04.697.650.895 C23.550.727.650.895
|
| Concept/Terms |
Neoplasms, Unknown Primary- Neoplasms, Unknown Primary
- Occult Primary Neoplasms
- Neoplasms, Occult Primary
- Neoplasm, Occult Primary
- Occult Primary Neoplasm
- Primary Neoplasm, Occult
- Primary Neoplasms, Occult
- Unknown Primary Neoplasms
- Neoplasm, Unknown Primary
- Primary Neoplasm, Unknown
- Primary Neoplasms, Unknown
- Unknown Primary Neoplasm
Unknown Primary Tumors- Unknown Primary Tumors
- Primary Tumor, Unknown
- Primary Tumors, Unknown
- Tumor, Unknown Primary
- Tumors, Unknown Primary
- Unknown Primary Tumor
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Unknown Primary".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Unknown Primary".
This graph shows the total number of publications written about "Neoplasms, Unknown Primary" by people in this website by year, and whether "Neoplasms, Unknown Primary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 3 | 0 | 3 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasms, Unknown Primary" by people in Profiles.
-
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary. Mol Ther. 2024 Oct 02; 32(10):3650-3668.
-
Utility of next-generation sequencing in the diagnosis of metastatic melanoma: A case report. J Cutan Pathol. 2024 Sep; 51(9):644-648.
-
Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe. JAMA Netw Open. 2024 02 05; 7(2):e2356479.
-
Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary Site. J Comput Assist Tomogr. 2024 Jul-Aug 01; 48(4):588-600.
-
Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study. J Natl Cancer Inst. 2023 08 08; 115(8):994-997.
-
Significance of Distinct Liquid Biopsy Compartments in Evaluating Somatic Mutations for Targeted Therapy Selection in Cancer of Unknown Primary. J Gastrointest Cancer. 2023 Dec; 54(4):1276-1285.
-
Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. Oncologist. 2022 10 01; 27(10):874-883.
-
Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol. 2022 07; 6:e2100547.
-
Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer. 2022 05; 10(5).
-
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022 01; 10(1).